Minimal residual disease-directed therapy in acute myeloid leukemia.

W. Zeijlemaker, J. W. Gratama, G. J. Schuurhuis, Tumor heterogeneity makes AML a “moving target” for detection of residual disease Cytometry Part B-clinical Cytometry. ,vol. 86, pp. 3- 14 ,(2013) , 10.1002/CYTO.B.21134

Moshe Yeshurun, Myriam Labopin, Didier Blaise, Jan J. Cornelissen, Henrik Sengeloev, Lars Vindelov, Juergen Kuball, Patrice Chevallier, Charles Craddock, Gerard Socie, Karin Bilger, Harry C. Schouten, Nathalie Fegueux, Hakan Goker, Johan Maertens, Donald Bunjes, Renate Arnold, Arnon Nagler, Mohamad Mohty, Impact of postremission consolidation chemotherapy on outcome after reduced‐intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation Cancer. ,vol. 120, pp. 855- 863 ,(2014) , 10.1002/CNCR.28498

Gustavo Milone, Mary M. Horowitz, Mary J. Laughlin, Robert Peter Gale, Waleska S. Perez, Mei-Jie Zhang, Daniel Weisdorf, Philip A. Rowlings, Selina M. Luger, Ruben A. Saez, Marcus R. Vowels, Jacob M. Rowe, Robert B. Geller, Armand Keating, Hillard M. Lazarus, Philip L. McCarthy, Martin S. Tallman, Effect of postremission chemotherapy before human leukocyte antigen–identical sibling transplantation for acute myelogenous leukemia in first complete remission Blood. ,vol. 96, pp. 1254- 1258 ,(2000) , 10.1182/BLOOD.V96.4.1254

Christopher S. Hourigan, Judith E. Karp, Minimal residual disease in acute myeloid leukaemia. Nature Reviews Clinical Oncology. ,vol. 10, pp. 460- 471 ,(2013) , 10.1038/NRCLINONC.2013.100

M Østergaard, C G Nyvold, J V Jovanovic, M T Andersen, V Kairisto, Y G Morgan, K Tobal, N Pallisgaard, U Özbek, H Pfeifer, S Schnittger, L Grubach, J K Larsen, D Grimwade, P Hokland, Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia. ,vol. 25, pp. 1168- 1173 ,(2011) , 10.1038/LEU.2011.69

C Allen, R K Hills, K Lamb, C Evans, S Tinsley, R Sellar, M O'Brien, J L Yin, A K Burnett, D C Linch, R E Gale, The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia Leukemia. ,vol. 27, pp. 1891- 1901 ,(2013) , 10.1038/LEU.2013.186

Susanne Schnittger, Martin Weisser, Claudia Schoch, Wolfgang Hiddemann, Torsten Haferlach, Wolfgang Kern, New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. ,vol. 102, pp. 2746- 2755 ,(2003) , 10.1182/BLOOD-2003-03-0880

Eric Jourdan, Nicolas Boissel, Sylvie Chevret, Eric Delabesse, Aline Renneville, Pascale Cornillet, Odile Blanchet, Jean-Michel Cayuela, Christian Recher, Emmanuel Raffoux, Jacques Delaunay, Arnaud Pigneux, Claude-Eric Bulabois, Céline Berthon, Cécile Pautas, Norbert Vey, Bruno Lioure, Xavier Thomas, Isabelle Luquet, Christine Terré, Philippe Guardiola, Marie C. Béné, Claude Preudhomme, Norbert Ifrah, Hervé Dombret, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia Blood. ,vol. 121, pp. 2213- 2223 ,(2013) , 10.1182/BLOOD-2012-10-462879

Peter Hokland, Hans Beier Ommen, Charlotte Guldborg Nyvold, Anne Stidsholt Roug, Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission – methodologies in relation to their clinical situation British Journal of Haematology. ,vol. 158, pp. 569- 580 ,(2012) , 10.1111/J.1365-2141.2012.09203.X

David Grimwade, Sylvie D. Freeman, Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Blood. ,vol. 124, pp. 3345- 3355 ,(2014) , 10.1182/BLOOD-2014-05-577593